|
MechanismKLKB1 inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismProtein kinase A (PKA) family inhibitors |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
An Open-Label, Single- and Multiple-Ascending-Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of Extended Release Formulations of ATN 249 in Healthy Male Participants
/ CompletedNot Applicable A Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending-Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ATN-249 in Healthy Male Participants
A randomized, double-blind, placebo-controlled, single-ascending–dose and two-way crossover food effect study to determine the safety, tolerability, pharmacokinetics and food effect of ATN-249 in healthy male participants
100 Clinical Results associated with Attune Pharmaceuticals, Inc.
0 Patents (Medical) associated with Attune Pharmaceuticals, Inc.
100 Deals associated with Attune Pharmaceuticals, Inc.
100 Translational Medicine associated with Attune Pharmaceuticals, Inc.